American Regent v. Somerset Therapeutics: Selenious Acid Patent Case Consolidated
American Regent, Inc. brought an infringement action against Somerset Therapeutics, LLC in New Jersey District Court, asserting two patents covering selenious acid selenium injection formulations. The case was consolidated with related proceedings within just 21 days of filing, suggesting parallel litigation activity in the same court over the same technology.
Rapid consolidation signals a broader selenium formulation patent campaign
On December 13, 2024, American Regent, Inc. filed an infringement action against Somerset Therapeutics, LLC in the U.S. District Court for the District of New Jersey, asserting two patents — US12150957B2 and US11998565B2 — covering selenious acid formulations used as injectable selenium supplements. The products at issue include selenious acid at three concentration variants: 600 mcg Selenium/10 mL, 60 mcg Selenium/mL, and 12 mcg Selenium/2 mL presentations.
The case closed on January 3, 2025 — just 21 days after filing — not through dismissal or settlement, but via consolidation into a related action pending in the same court. The court’s order directed that all future filings in the consolidated action use a unified caption going forward. This procedural outcome means the substantive infringement claims remain alive and will be litigated together with at least one other related case.
The speed of consolidation — within three weeks of filing — strongly suggests American Regent had already initiated at least one other related case in the same district before or around the same time, consistent with a coordinated multi-defendant or multi-product enforcement strategy. The public record does not disclose the identity of the lead case, the full scope of consolidation, or whether Somerset Therapeutics has retained counsel or filed any responsive pleadings.
Filing to Case Consolidated in 21 days
21 days from filing to consolidation — well below average district court resolution timelines
Case consolidated: what this means for the ongoing infringement action
Consolidation is procedural — the case is not over
When a federal district court consolidates cases, it merges related actions under a single caption to avoid duplicative proceedings and inconsistent rulings. The underlying infringement claims are not dismissed and no merits ruling has been issued. The court simply determined that this action shares common questions of law or fact with at least one other pending case, typically involving the same patents or the same accused products.
Active infringement claims remainAmerican Regent retains all claims in the consolidated action
Consolidation does not prejudice American Regent’s infringement claims. The plaintiff continues to pursue enforcement of US12150957B2 and US11998565B2 against Somerset Therapeutics within the unified proceeding. If the consolidated action involves multiple defendants or related products, American Regent may benefit from economies of litigation — shared discovery, unified claim construction, and a single trial record — potentially strengthening its overall enforcement posture.
Claims fully preservedSomerset Therapeutics must defend in a potentially broader consolidated proceeding
Somerset Therapeutics now faces litigation within a consolidated framework that may include other defendants or additional accused products. This can increase the complexity and cost of defense. The public record does not confirm whether Somerset has retained counsel or responded to the complaint. Absent a response, default risk escalates. The consolidation also means Somerset’s litigation strategy may be influenced by co-defendants or parallel validity challenges it did not initiate.
Defense complexity elevatedCoordinated enforcement signals serious exclusivity intent over selenium injectables
The rapid consolidation of this action suggests American Regent is running a coordinated patent enforcement campaign over its selenious acid injectable portfolio. For generic and specialty pharmaceutical companies developing selenium parenteral products, this pattern typically signals that the patent holder views its formulation IP as a meaningful competitive barrier. Companies with ANDA filings or commercialised products in this concentration range should treat these patents as high-priority FTO targets.
Multi-case enforcement patternFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical injectable products company — holder of US12150957B2 and US11998565B2Search in Eureka ↗ |
| Defendant | Somerset Therapeutics, LLC | Company | Somerset Therapeutics, LLC — generic/specialty pharmaceutical manufacturer and distributorSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order — directing that all filings in the consolidated action use a unified caption going forward — is purely procedural and carries no merits determination on infringement, validity, or damages. It confirms only that this action has been merged with at least one related case. The phrasing ‘Consolidated Action’ in the verdict suggests a formal consolidation order under Fed. R. Civ. P. 42(a), not a voluntary dismissal or settlement. All substantive claims remain pending.
US12150957B2 & US11998565B2 — Selenious Acid Injectable Selenium Formulations
US12150957B2 (App. No. US18/672876) and US11998565B2 (App. No. US18/124391) both cover selenious acid compositions used as injectable selenium supplements in parenteral nutrition settings. These are relatively recently issued utility patents protecting specific concentration formulations — including 60 mcg Selenium/mL and 6 mcg Selenium/mL presentations — that are clinically used to prevent or treat selenium deficiency in patients receiving intravenous nutrition.
Selenium injectables occupy a specialist niche within the parenteral nutrition market, and formulation-specific patents in this space can provide meaningful exclusivity against generic ANDA filers. The assertion of two distinct patents covering the same product line — filed via separate application numbers — suggests a deliberate portfolio layering strategy by American Regent. For competitors, the overlapping protection across multiple concentration variants substantially narrows the space for generic or biosimilar development without FTO clearance.
Should your selenious acid injectable product be cleared against US12150957B2?
Any pharmaceutical company developing, manufacturing, or seeking ANDA approval for selenious acid injectable products — particularly those formulated at 60 mcg Selenium/mL or 6 mcg Selenium/mL — should treat US12150957B2 and US11998565B2 as priority FTO targets. The active consolidated litigation in New Jersey and the multi-defendant enforcement pattern mean that market entry without claim clearance carries material litigation risk, including potential 30-month ANDA stay exposure if these patents are Orange Book-listed.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claim scope of both asserted patents against your product’s formulation parameters, identify prior art that may support invalidity arguments, and flag any continuation or divisional applications still pending in American Regent’s portfolio. Monitoring this patent family for new grants or claim amendments is equally important given the active litigation context.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar selenious acid and parenteral nutrition patent cases in NJ District Court
Explore related pharmaceutical formulation infringement actions in the New Jersey District Court involving injectable trace element and parenteral nutrition patents.
What this case signals for the injectable selenium pharmaceutical IP landscape
American Regent’s rapid, multi-case enforcement in New Jersey marks a clear escalation in selenious acid formulation patent strategy.
Consolidation within 21 days points to a pre-planned litigation campaign
Cases consolidated this quickly after filing typically reflect a deliberate plaintiff strategy — filing related actions simultaneously or in close succession and then seeking to unify them. For competitors in the parenteral nutrition and trace element injectable space, this suggests American Regent’s IP team is actively monitoring the market and is prepared to litigate across multiple defendants.
Two recently issued patents create a layered formulation IP fence
US12150957B2 and US11998565B2 both relate to selenious acid selenium injectable formulations and were filed via separate application numbers, suggesting distinct but complementary claim scope. A two-patent assertion at filing — rather than a single patent — raises the invalidity and design-around burden for any accused generic manufacturer, including Somerset Therapeutics.
American v Somerset — key questions answered
American Regent, Inc. filed an infringement action against Somerset Therapeutics, LLC in the New Jersey District Court on December 13, 2024, asserting US12150957B2 and US11998565B2 over selenious acid injectable selenium products. The case was consolidated into a related action on January 3, 2025 — 21 days after filing — with all future filings to proceed under a unified caption. No merits ruling was issued.
American Regent asserted two patents: US12150957B2 (Application No. US18/672876) and US11998565B2 (Application No. US18/124391). Both cover selenious acid formulations used as injectable selenium supplements, including products at 600 mcg Selenium/10 mL, 60 mcg Selenium/mL, and 12 mcg Selenium/2 mL concentrations.
Case consolidation under Fed. R. Civ. P. 42(a) means the court has merged two or more related actions into a single proceeding to avoid duplicate litigation and inconsistent outcomes. The case is not dismissed and no ruling on the merits is made. All infringement claims remain active and will be litigated in the consolidated action. The docket is closed only as a separate matter, not as a resolved dispute.
The 21-day timeline from filing to consolidation suggests American Regent had already filed at least one related case in the same district — likely asserting the same patents against the same or a different defendant — before or around the same time. Rapid consolidation of this kind is consistent with a coordinated, multi-case enforcement strategy rather than an isolated dispute. The public record does not identify the lead consolidated case.
Companies with ANDA filings or commercialised products matching the accused concentration ranges — particularly 60 mcg Selenium/mL and 6 mcg Selenium/mL — face direct infringement exposure. If US12150957B2 or US11998565B2 are listed in the FDA Orange Book, a Paragraph IV ANDA certification would trigger a 30-month litigation stay. The dual-patent assertion and active consolidated litigation in New Jersey materially raise the risk profile for any generic market entrant in this product class.
PatSnap Eureka searches patents and litigation data to answer instantly.